Volume 16, Issue 2, Pages 221-232 (February 2015) Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial  Prof Jordi Giralt, MD, Jose Trigo, MD, Prof Sandra Nuyts, MD, Mahmut Ozsahin, MD, Krzysztof Skladowski, MD, Georges Hatoum, MD, Jean-Francois Daisne, MD, Alejandro César Yunes Ancona, MD, Prof Anthony Cmelak, MD, Prof Ricard Mesía, MD, Alicia Zhang, PhD, Kelly S Oliner, PhD, Ari VanderWalde, MD  The Lancet Oncology  Volume 16, Issue 2, Pages 221-232 (February 2015) DOI: 10.1016/S1470-2045(14)71200-8 Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 1 Trial profile *One patient received only radiotherapy and not panitumumab and was not included in the safety analyses. The Lancet Oncology 2015 16, 221-232DOI: (10.1016/S1470-2045(14)71200-8) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 2 Kaplan-Meier distribution curves of local-regional control, progression-free survival, and overall survival in the efficacy analysis set (A) Local-regional control, calculated from the first day of any study treatment (radiotherapy, chemotherapy, or panitumumab if applicable) to the date of first local-regional failure or to death due to any cause (whichever occurred first). Patients who did not have regional recurrence by the data cutoff were censored at last local-regional control assessment date or tumour assessment date (if no local-regional control assessment had been done). (B) Progression-free survival, defined as time from the first day of any study treatment to date of first disease progression per WHO criteria or death; patients not meeting these criteria by the analysis data cutoff date had their progression-free survival time censored at their last evaluable disease assessment date. (C) Overall survival, defined as time from the first day of study treatment to date of death; patients who had not died by the analysis data cutoff date were censored at their last contact date. HR=hazard ratio. The Lancet Oncology 2015 16, 221-232DOI: (10.1016/S1470-2045(14)71200-8) Copyright © 2015 Elsevier Ltd Terms and Conditions

Figure 3 Forest plots of progression-free and overall survival according to HPV status, measured by extent of p16 positivity in tumour sample Progression-free and overall survival according to p16 positivity when defined as uniform staining in 10% or more of tumour cells (A) and when defined as uniform staining in 70% or more of tumour cells (B). CRT=chemoradiotherapy. HPV=human papillomavirus. HR=hazard ratio. PaRT=radiotherapy plus panitumumab. The Lancet Oncology 2015 16, 221-232DOI: (10.1016/S1470-2045(14)71200-8) Copyright © 2015 Elsevier Ltd Terms and Conditions